Investor Presentaiton
Q3FY24 - Key Business & Financial Highlights
Total Revenue stood at INR 7,956 mn | Pharma Export Formulations at INR 6,056 mn | Domestic Formulations at INR 994 mn | Agchem
at INR 141 mn
Earnings Before Interest Tax Depreciation and Amortization stood at INR 3,051 mn | EBITDA Margin for Q3FY24 was at 38.4%
Net Profit for the quarter was at INR 2,127 mn
Basic and Diluted EPS for the quarter is INR 11.88 per share
Board has approved third interim dividend of INR 1.25 per equity share of INR 2/- for the year FY23-24
Investment of US$2mn in Cellogen Therapeutics Private Ltd., with R&D programs involving cell and gene therapy solutions
*EBITDA and EBITDA Margin includes other income
Natco Pharma Limited - Earnings Presentation - Q3FY24
5View entire presentation